## 3V INVEST SWISS SMALL & MID CAP

#### **MARCH 2024**

**Sector Weightings** 


**TOP 12 Positions** 


## The interest rate turnaround is happening


For once, the Swiss National Bank (SNB) is ahead of the European Central Bank (ECB) and the US Federal Reserve. Low inflation in Switzerland has allowed the SNB to cut its key interest rate from 1.75% to 1.5% in March, making it the first of the leading central banks to herald a turnaround in interest rates. This move weakens the Swiss franc and should be beneficial to economic growth in Switzerland. The 3V Invest Swiss Small & Mid Cap improved by 3.9% in March. Our benchmark SPI Small & Middle Companies Index rose by 2.6% in the same period. On the corporate side, Swissquote impressed with a record result. The 95% increase in the dividend and the management's positive outlook should support further share price gains. We continue to view the share's valuation as moderate. The intralogistics company Interroll recorded a decline in sales, but was able to protect its profitability thanks to strict cost control. We believe that the downturn has bottomed out and that Interroll is well positioned for the upturn. The demand for automated solutions is particularly high in times of a shortage of skilled workers. Aryzta exceeded analysts' expectations with its figures. Encouragingly, the turnaround is continuing and operating profitability has increased further despite the inflationary environment. The high free cash flow allows debt to be reduced, ensures lower financing costs and improves the quality of the balance sheet. The company should soon be able to pay dividends again. In March, the dermatology company Galderma took the chance and went public. We consider the price range on offer and the structurally growing business to be attractive and therefore participated in the IPO. In the reporting period, we also increased our weighting in the shares of Medmix and Medacta.

# In the Spotlight: Bachem

Thanks to strong business performance in the second half of the year, pharmaceutical contract manufacturer Bachem exceeded expectations with its figures for 2023. Much more decisive for the positive share price reaction (+23% in the month under review) were the statements on the commissioning of the new production building. Bachem is excellently positioned in the diabetes segment and in the market for products to combat obesity. Demand for the obesity drugs from Eli Lilly and Novo Nordisk is enormous, so it is hardly surprising that capacities are far too low in view of this demand. As a technology leader, Bachem should benefit greatly from this positive market dynamic, especially with additional capacity.







Swiss Small & Mid Cap Fund



6.2 %

2.6 %

#### Investment universe and investment style

+0.5 % +1.7 % +3.9 %

+0.8 % +2.6 %

Our investment universe consists of all companies in the SIX Swiss Exchange's SPI Small and Middle Companies Index. This comprises roughly 200 stocks. Up to 20% of fund assets can be invested in companies listed in the SPI Large Companies Index. 3V Asset Management takes a high-conviction approach that differs substantially from the index and invests in 30 to 35 companies. Stock picking is based on fundamental analysis, taking ESG criteria into account. Companies violating social and ecological criteria are excluded.

Key Figures Fund		
Net Asset Value Class A as of	28.03.2024	CHF 293.67
Total Fund Assets as of	28.03.2024	CHF 169 Mio

Risk Key Figures (since January 1st, 2019)						
Volatility p.a.	18.3 %					
Sharpe Ratio	0.17x					
Tracking Error	4.7 %					
Active Share	68.6 %					

Yearly Peri	formance *	* a	as of 28.03	.2024									
	2016	2017	2018	2019	2020	2021	2022	2023	2024				
Fund	14.2 %	32.0 %	-28.1 %	30.7 %	15.2 %	22.1 %	-29.4 %	11.3 %	6.2 %				
SPI SMC	9.0 %	29.7 %	-16.4 %	30.0 %	8.0 %	20.3 %	-22.0 %	9.6 %	2.6 %				
Monthly P	erformanc	<b>e</b> * 2	as of 28.03	.2024									
	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	Year

Termsheet
-----------

ESG

SPI SMC -0.8 %

Fund

3V Invest Swiss Small & Mid Cap Fund (Class A)
3V Asset Management AG (Martin Lehmann)
Valor: 977433 / WKN: 989282 / ISIN: LU0092739993
OPPDAVF LX Equity
SPI Small & Middle Companies
1.5% p.a. (TER 1.8%)
VP Fund Solutions (Luxembourg) SA / VP Bank (Luxembourg) SA
daily, subscriptions & redemptions until 4 pm Swiss Time at Net Asset Value
distribution license for Switzerland, Germany, Austria and Luxembourg
none / CHF
BNP Paribas Securities Services, Paris, succursale de Zurich, 8002 Zurich

MSCI ESG AA, Article 8-Fund

This is a marketing advertisement. It is intended solely for the personal use of the recipient and may not be duplicated, shared with third parties or published electronically or in any other form. The information contained does not constitute an offer to buy or sell a financial instrument, investment advice or any other recommendation. It is provided for information purposes only. 3V Asset Management AG accepts no responsibility for the completeness and correctness of the information presented. Please read the prospectus of the 3V Invest Swiss Small & Mid Cap Fund and the KIID before making a final investment decision. Representative of this fund under Luxembourg law in Switzerland is BNP Paribas Securities, Paris, succursale de Zurich. Sales prospectuses as well as the latest annual and semi-annual reports can be obtained free of charge from BNP Paribas Securities, Paris, succursale de Zurich. The units of the fund may only be offered, sold or delivered under those jurisdictions which deem this permissible. Units of this investment fund may not a specific underlying asset. The value of this share may go down as well as value cannot be ruled out. No guarantee is given that investment objectives will be achieved Historical performance data is no guarantee of future performance. It is up to the investor to inform himself about tax aspects. These depend on the personal situation of the respective investor and may change in the future.



<sup>\*</sup> Past performance is not indicative of future returns